Diagnostic tests based on the detection of DNA from harmful organisms in clinical samples have revolutionized veterinary medicine in the last decades. Currently, diagnostic panels for several vectorborne diseases (VBDs) are available through universities and private labs in the USA and abroad. Continue reading “Research Update CHF 02528 EY3: Developing a Next Generation Sequencing Diagnostic Platform for Tick-Borne Diseases”
To date, we have screened 31 dogs for the SLIM study. Of these, 23 have met the inclusion criteria and were enrolled. Of these enrolled dogs, six dogs have completed at least 12 weeks of the 24-week clinical trial. We are averaging 1-2 dogs screening for the study per week. Therefore, we are currently on track to have all dogs enrolled by Fall 2021. Continue reading “Research Update CHF 02723 EY1: Scientific and Clinical Assessment of Fecal Microbiota Transplant in Obese Dogs: SLIM Study”
Data collected over the 15 years of the 9/11 study represents a massive amount of never before available information on the short and long-term impacts of a search & rescue deployment on the health and behavior of the search dog. Continue reading “Research Update CHF 02322 EY-4: Analysis of the Health, Behavioral, and Longevity Data Collected in the 9/11 Medical Surveillance Longitudinal Study”
We have met our Labrador Retriever recruitment for this study over the past six months. We will continue to complete DNA isolation and marker genotyping of the remaining dogs needed for the study as long as the genotyping service remains open under the Covid-19 pandemic. Public engagement with the project continues to be good.
Over the next 6 months, we will focus on finalizing the marker data set for the study for which we do not yet have SNP genotypes. We will then undertake the computing needed to robustly estimate the heritability of cruciate ligament rupture in the Labrador Retriever and further advance prediction of risk of disease using the genomic marker data.
Our final data set is expected to include more than 1,000 Labrador Retriever dogs as promised under the award. We are extremely grateful for the outstanding engagement with this project by the community of Labrador Retriever owners and breeders that we work with.
Soft tissue sarcoma (STS) encompasses a number of neoplasms that are derived from mesenchymal cells including fibrosarcoma, myxosarcoma, hemangiopericytoma, and undifferentiated sarcoma. In the dog, STSs arise frequently in the dermis/subcutis and represent up to 15% of the neoplasms in this location. Our primary aim of this grant was to collect cases of canine STS for histologic and gene expression analysis. Continue reading “Research Update CHF 02783 EY1: Transcriptional Profiling of Canine Soft Tissue Sarcoma”
Right after our AKC Canine Health Foundation grant funding started in March 2020, our lab was closed for 3 months due to COVD-19 and has since been limited to 50% occupancy. In addition, our teaching hospital has had limited appointments since March 2020.
We finished a few validation experiments on our DNA damage assays that were needed before recruitment, and we have started recruiting dogs with bladder cancer and matched controls. We enrolled our first two new cases and two controls this month. Continue reading “Research Update CHF 02780 EY1: Bladder Carcinogen Exposures in Pet Dogs”
Thank you for supporting our project titled “Optical coherence tomography for margin evaluation of skin and subcutaneous neoplasms”. This project is investigating an emerging diagnostic imaging tool, optical coherence tomography that uses light waves to generate real time high-resolution images of tissues for detection of residual cancer cells immediately following surgical removal. Our team involves collaboration between veterinary medicine and pathology at the Ohio State University. We have had excellent progress in our patient enrollment, we completed enrollment of the 80 cases planned already! Continue reading “Research Update CHF 02758 EY1: Optical Coherence Tomography for Margin Evaluation of Canine Skin and Subcutaneous Neoplasms”
We have successfully developed a canine cancer gene panel that we have called the Canine Oncopanel, using cutting-edge, next-generation sequencing technology (NGS). The Canine Oncopanel allows sequencing of 283 cancer-related genes and detection of mutations within these genes that may drive the tumor cells to proliferate and survive. The canine oncopanel sequences a total target region that equates to ~3% of the canine genome. Analyzing the genomic composition of this broad target region allows evaluation of common genomic alterations that can lead to the development of cancer. The Canine Oncopanel is suitable to map mutation profiles and identify driver mechanisms in both common and rare canine cancers to provide a better understanding of the tumor genome and its biology.
The study titled “Investigation into Subclinical Diet- associated Dilated Cardiomyopathy in Four Dog Breeds” is progressing on schedule and nearing completion. Enrollment for the first part of the study is complete and a peer-reviewed manuscript describing the results has been published in the Journal of Veterinary Internal Medicine (DOI: 10.1111/jvim.16075). The results of this part of the study showed higher levels for cardiac troponin I in dogs eating grain-free dog foods or foods that have peas, lentils or potatoes in the top 10 ingredients. Cardiac troponin I is a blood marker that indicates injury to the heart muscle. Even mild elevations can be important but future studies will be needed to determine with certainty that this is the case in these dogs. We did not find echocardiographic (heart ultrasound) differences between dogs eating grain-free and grain-inclusive foods. If the low-level elevation of cardiac troponin I truly indicates low-level heart muscle injury then it may be too early in these healthy dogs to manifest as echocardiographic differences.
The goal for this project is to develop a reliable, accessible, and actionable test to identify dogs at risk for hemangiosarcoma during the earliest stages of disease and to use a strategic, rationally designed approach to prevent its occurrence in these high-risk dogs before it becomes clinically detrimental and life-threatening. The study has two objectives. The first is to determine the most reasonable duration of an SOS test result. In other words, how long can a low-risk SOS test result be trusted and how much time might elapse between a high-risk SOS test result and the development of hemangiosarcoma. The second aim is to continue periodic testing for dogs previously enrolled in the Shine On study whose test result would have placed them in a high-risk category for development of hemangiosarcoma, and to provide eBAT as a strategy for prevention in 12 of these dogs. Continue reading “Research Update CHF 02806-MOU MY1: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up”